Mark Matson - Concepedia

Author

Mark Matson

Prism Clinical Research

Also Known As

M. Matson, M.A. Matson, MARK A. MATSON, Mark A Matson, Mark A. Matson, Mark Matson

Publications

931

Citations

H-Index

Concepts

All Affiliations

Prism Clinical Research Biogen (United States)Hennepin County Medical Center Rho (United States)Astellas Pharma (United States)

About

Mark Matson is an author at Prism Clinical Research specializing in medicine, pharmacology, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	699
2	Allergy	1	1	167
3	Clinical Immunology	1	1	14
4	Diabetes	1	1	12
5	Gastroenterology	1	1	167

Mark Matson

Publications

880

Citations

H-Index

Page 1

	Year	Citations
Acquired Cystic Kidney Disease Mark Matson, Eric P. Cohen Medicine Glomerular DiseaseNative Kidney RetentionPathologyCarcinomaGlomerulonephritis	1990	248
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Clapton Dias, Adam J. Shaywitz, Scott M. Wasserman, Journal of the American College of Cardiology Cardiovascular DiseaseMedicineHyperlipidemiaPharmacologyAtherosclerosis	2012	233
TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study Ciarán P. Kelly, Joseph A. Murray, Daniel A. Leffler, Gastroenterology Food IntoleranceAutoimmune DiseaseAllergyImmunologyGastroenterology	2021	167
Pharmacokinetics and Pharmacodynamics of MK‐5046, a Bombesin Receptor Subtype‐3 (BRS‐3) Agonist, in Healthy Patients Marc L. Reitman, Victor Dishy, Allison Moreau, The Journal of Clinical Pharmacology	2011	44
Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers Helen S. Pentikis, Mark Matson, George Atiee, Antimicrobial Agents and Chemotherapy	2011	37
Long-term Follow-up of 369 Diabetic Patients Undergoing Dialysis Mark Matson Archives of Internal Medicine	1988	36
Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects Ying Cao, Taiji Sawamoto, Udaya Valluri, Clinical Pharmacology in Drug Development	2016	29
Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers Nandita Bose, Nadine Ottoson, Xiaohong Qiu, The Journal of Immunology Clinical ImmunologyImmunodeficienciesImmunologyImmune RegulationImmunotherapeutics	2019	14
460 A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS Joseph M. Patti, Mark Matson, Brian Boehlecke, Journal of Hepatology Drug SafetyPharmacokinetic ModelingPharmacologyClinical PharmacologyPharmacotherapy	2011	13
Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: a comparative phase 2/3 trial Mark Matson, Eran Schenker, Michal Stein, Human Vaccines & Immunotherapeutics	2019	13

Page 1